WO2022243913 - COMPOSITIONS AND METHODS FOR ENHANCING VISUAL FUNCTION
National phase entry is expected:
Publication Number
WO/2022/243913
Publication Date
24.11.2022
International Application No.
PCT/IB2022/054650
International Filing Date
19.05.2022
Title **
[English]
COMPOSITIONS AND METHODS FOR ENHANCING VISUAL FUNCTION
[French]
COMPOSITIONS ET PROCÉDÉS D'AMÉLIORATION DE LA FONCTION VISUELLE
Applicants **
NOVARTIS AG
Lichtstrasse 35
4056 Basel, CH
Inventors
GUERIN, Karen I.
Vedere Bio II, Inc.
300 Technology Square, 8th Floor
Cambridge, Massachusetts 02139, US
KOTIN, Robert M.
2 Potter Park, Unit 2
Cambridge, Massachusetts 02138, US
PASTOR, Eric
67 Elgin Street
Apt #1
Newton, Massachusetts 02459, US
REN, Xiaozhi
Vedere Bio II, Inc.
300 Technology Square, 8th Floor
Cambridge, Massachusetts 02139, US
YOUNG, Sharon
ATUM
37950 Central Court
Newark, California 94560, US
Priority Data
63/191,525
21.05.2021
US
63/292,746
22.12.2021
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 2918 | |
| EPO | Filing, Examination | 25489 | |
| Japan | Filing | 590 | |
| South Korea | Filing | 607 | |
| USA | Filing, Examination | 15360 |
Total: 44964 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The present disclosure provides compositions and methods of restoring or enhancing visual function in an individual by administering to the individual a pharmaceutical composition comprising a recombinant adeno-associated viral (rAAV) vector having a polynucleotide sequence that encodes a medium wavelength cone opsin (MW-opsin). The MW-opsin is expressed in a retinal cell in the individual, thereby restoring or enhancing visual function.[French]
La présente invention concerne des compositions et des procédés de restauration ou d'amélioration de la fonction visuelle chez un individu par administration à l'individu d'une composition pharmaceutique comprenant un vecteur de virus adéno-associé recombinant (rAAV) ayant une séquence polynucléotidique qui code pour une opsine de cône à longueur d'onde moyenne (MW-opsine). La MW-opsine est exprimée dans une cellule rétinienne chez l'individu, ce qui permet de restaurer ou d'améliorer la fonction visuelle.